The Plague drugs in development market research report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Plague. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Plague and features dormant and discontinued products.

GlobalData tracks 18 drugs in development for Plague by 18 companies/universities/institutes. The top development phase for Plague is preclinical with 12 drugs in that stage. The Plague pipeline has nine drugs in development by companies and nine by universities/ institutes. Some of the companies in the Plague pipeline products market are: University of Strathclyde, Prokarium and iBio.

The key targets in the Plague pipeline products market include Yersinia pestis Protein Tyrosine Phosphatase YopH (Targeted Effector Protein or Virulence Protein or yopH or EC 3.1.3.48), Yersinia pestis Virulence Associated V Antigen (Low Calcium Response Locus Protein V or lcrV), and Peptidyl Prolyl Cis Trans Isomerase FKBP5 (HSP90 Binding Immunophilin or 51 kDa FK506 Binding Protein or FK506 Binding Protein 5 or Androgen Regulated Protein 6 or FF1 Antigen or FKBP51 or FKBP54 or FKBP5 or EC 5.2.1.8).

The key mechanisms of action in the Plague pipeline product include Protein Tyrosine Phosphatase (EC 3.1.3.48) Inhibitor with one drug in Discovery. The Plague pipeline products include six routes of administration with the top ROA being Intramuscular and six key molecule types in the Plague pipeline products market including Subunit Vaccine, and Recombinant Vector Vaccine.

Plague overview

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents, or when human handle infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock, and bleeding from the mouth, nose, ectum, or under the skin. Treatment includes antibiotics.

For a complete picture of Plague’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.